缺血性心脏病中维拉帕米的应用——通过连续多阶段平板运动进行定量评估
Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise.
作者信息
Balasubramanian V, Khanna P K, Naryanan G R, Hoon R S
出版信息
Postgrad Med J. 1976 Mar;52(605):143-7. doi: 10.1136/pgmj.52.605.143.
The efficacy of verapamil in a dose of 120 mg thrice daily was assessed by an objective protocol. Twenty-five patients with ischaemic heart disease were subjected to serial, measured multistage treadmill exercise without any drugs, and after propranolol 40 mg t.d.s. for 3 days to assess the stress response to beta-blockade. The tests were repeated after 2, 4 and 8 weeks of verapamil. The assessment was based on computerized ST segment changes, the anginal threshold and other objective parameters. Verapamil rendered eight out of thirteen symptomatic patients pain free and significantly increased the anginal threshold in all others. The ischaemic response as assessed by the ST segment changes on exercise showed a marked improvement in the symptomatic as well as the asymptomatic groups. No major side effects were encountered throughout the study. It was concluded that verapamil in a dose of 360 mg/day is an effective antianginal agent free from significant side effects.
通过客观方案评估了每日三次服用120毫克维拉帕米的疗效。25名缺血性心脏病患者在未服用任何药物的情况下进行了连续、测量的多阶段跑步机运动，并在服用普萘洛尔40毫克每日三次，共3天以评估对β受体阻滞剂的应激反应后进行了测试。在服用维拉帕米2、4和8周后重复进行测试。评估基于计算机化的ST段变化、心绞痛阈值和其他客观参数。维拉帕米使13名有症状的患者中的8名无痛，并使所有其他患者的心绞痛阈值显著提高。通过运动时ST段变化评估的缺血反应在有症状和无症状组中均有明显改善。在整个研究过程中未遇到重大副作用。得出的结论是，每日剂量为360毫克的维拉帕米是一种有效的抗心绞痛药物，且无明显副作用。
Zotero 插件